The essentials
Two mifepristone manufacturers are appealing the Fifth Circuit's block on mail and telehealth distribution to higher courts.
Following the Fifth Circuit Court of Appeals' decision to block telehealth and mail distribution of mifepristone, two major manufacturers are pursuing appeals to overturn the ruling. Danco Laboratories has requested a Supreme Court stay of the Fifth Circuit decision, seeking immediate intervention from the nation's highest court. GenBioPro is also planning to appeal the Fifth Circuit ruling, signaling coordinated manufacturer resistance to the court-imposed restrictions.
The Fifth Circuit ruling, issued from New Orleans, eliminated mail delivery and telehealth prescribing as distribution methods for mifepristone, the medication used in medical abortions. The manufacturer appeals represent a direct challenge to the lower court's authority to restrict FDA-approved distribution pathways, introducing private pharmaceutical interests into ongoing litigation alongside state and federal actors. These appeals advance the legal dispute toward potential Supreme Court review, where the medication's distribution methods face continued contestation despite its established FDA approval status.
Other ways to read this story.
Alternative framings generated by SigNews. These are not independent sources or attributed quotations.
Manufacturers pursue simultaneous appeals to reverse Fifth Circuit restrictions
Danco Laboratories and GenBioPro are both advancing appeals of the Fifth Circuit ruling that blocked mifepristone mailing and telehealth distribution. Danco has specifically requested a Supreme Court stay, indicating a direct escalation to the highest court rather than intermediate appellate proceedings. This dual-track appeal strategy reflects manufacturer determination to challenge the Fifth Circuit's authority to restrict FDA-approved distribution methods through multiple judicial pathways simultaneously.
Fifth Circuit ruling faces immediate appeal as manufacturers seek reversal
The Fifth Circuit Court of Appeals' decision blocking mifepristone mail distribution has triggered manufacturer appeals that will test the ruling's legal stability. Danco's Supreme Court stay request represents an emergency procedural motion, attempting to halt the Fifth Circuit's restrictions before they take full effect. GenBioPro's planned appeal introduces additional litigation challenging the same Fifth Circuit decision, potentially creating multiple review pathways within the appellate system.